Aspirantskiy Vestnik PovolzhiyaAspirantskiy Vestnik Povolzhiya2072-23542410-3764Samara State Medical University2532310.17816/2072-2354.2018.18.3.107-112Review ArticleСHROMOGRANIN A AS A POTENTIAL MARKER OF A CARDIOVASCULAR RISK IN PATIENTS WITH ESSENTIAL HYPERTENSION (LITERATURE REVIEW)GubarevaE YuPostgraduate student of the Internal Diseases Department, Samara State Medical University.ekaterina.ju.gubareva@gmail.comKryukovN NHonoured Science Worker of Russia, Doctor of Medical Sciences, Professor, Head of the Internal Diseases Department, Samara State Medical University.kaferdravb@yandex.ruGubarevaI VDoctor of Medicine, Associate Professor, Internal Diseases Department, Samara State Medical Universityirigub@rambler.ruZheltyakovaO VCandidate of Biological Sciences, Head of Clinical-diagnostic Laboratory at the «Road Сlinical Hospital at the station of Samara ОJSC “Russian Railways”akola71@mail.ruMartynenkoI DMaster’s student of ETU “LETI”, Field of training No. 12.04.04 Biotechnical systems and technologies, Profile 12.04.04-57 Biotechnical systems and technologies of environmental protection.program4u@ya.ruSamara State Medical UniversityNon-State Healthcare Institution “Road Сlinical Hospital at the station of Samara ОJSC “Russian Railways”St. Petersburg Electrotechnical University ETU (LETI)15092018185-610711211032020Copyright © 2018, Gubareva E.Y., Kryukov N.N., Gubareva I.V., Zheltyakova O.V., Martynenko I.D.2018Recent clinical studies demonstrate the possibility of glycoprotein chromogranin A (CgA) use not only for the diagnosis of neuroendocrine tumors and secondary hypertension, but also as the essential hypertension (EH) and associated states cardiovascular risk marker. However, the evidence base is small and contradictory. The article presents a review of key studies on the topic, arguing the use of CgA in patients with EH.essential hypertensioncardiovascular riskmarkerschromogranin Aгипертоническая болезньсердечно-сосудистый рискмаркерыхромогранин А[Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ // Кардиоваскулярная терапия и профилактика. - 2014. - Т 13. - № 4. - С. 4-14][Казидаева Е.Н., Веневцева Ю.Л. Взаимосвязь показателей полифункционального мониторирования у молодых людей с прегипертензией или мягкой артериальной гипертензией, имеющих разный суточный профиль артериального давления // Артериальная гипертензия. - 2013. - Т. 19. - № 1. - С. 44-50][Кобалава Ж.Д., Котовская Ю.В., Моисеева В.С. Артериальная гипертония. Ключи к диагностике и лечению. - М.: ГЭОТАР-Медиа, 2009][Рогоза А.Н., Ощепкова Е.В., Цагареишвили Е.В. Современные неинвазивные методы измерения артериального давления для диагностики артериальной гипертонии и оценки эффективности антигипертензивной терапии: пособие для врачей. - М.: МЕДИКА, 2007][Конради А.О., Захаров Д.В., Рудоманов О.Г., и др. Спектральный анализ вариабельности ритма сердца при различных вариантах ремоделирования левого желудочка у больных гипертонической болезнью // Артериальная гипертензия. - 2000. - Т. 6. - № 2. - С. 33-38][Турна Э.Ю., Крючкова О.Н. Анализ показателей суточной динамики артериального давления, вариабельности сердечного ритма и скорости клубочковой фильтрации пациентов с артериальной гипертензией, перенесших ишемический инсульт // Молодой ученый. - 2012. - № 12. - С. 562-566][Явелов И.С. Вариабельность сердечного ритма при сердечно-сосудистых заболеваниях: взгляд клинициста // Сердце: журнал для практикующих врачей. - 2006. - Т. 5. - № 1. - C. 18-23][Choi Y, Miura M, Nakata Y, et al. A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population. Endocr J. 2015;62(9):797-804. doi: 10.1507/endocrj.EJ14-0471][Subramanian L, Khan AA, Allu PKR, et al. A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders. J Biol Chem. 2017;292(34):13970-13985. doi: 10.1074/jbc.M117.778134][Bandyopadhyay GK, Mahata SK. Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity. Front Endocrinol (Lausanne). 2017;8:20. doi: 10.3389/fendo.2017.00020][Wen G, Mahata SK, Cadman P, et al. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet. 2004;74(2):197-207. doi: 10.1086/381399][Rao F, Wen G, Gayen JR, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115(17):2271-2281. doi: 10.1161/CIRCULATIONAHA.106.628859][Kiranmayi M, Chirasani VR, Allu PK, et al. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. Hypertension. 2016;68(2):334-347. doi: 10.1161/HYPERTENSIONAHA.116.06568][Chen Y, Rao F, Rodriguez-Flores JL, et al. Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int. 2008;74(1):115-125. doi: 10.1038/ki.2008.113][Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor-alpha (TNF) in chronic heart failure. Adv Exp Med Biol. 2000;482:351-359. doi: 10.1007/0-306-46837-9_28][Hsiao RJ, Parmer RJ, Takiyyuddin MA, O’Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991;70(1):33-45][Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23(12):967-974. doi: 10.1053/euhj.2001.2977][Salem RM, Cadman PE, Chen Y, et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol. 2008;19(3):600-614. doi: 10.1681/ASN.2007070754][Manhenke C, Orn S, von Haehling S, et al. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol. 2013;166(3):729-735. doi: 10.1016/j.ijcard.2011.11.089][Vaingankar SM, Li Y, Biswas N, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens. 2010;28(4):817-825. doi: 10.1097/HJH.0b013e328336ed3e][Capellino S, Lowin T, Angele P, et al. Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2008;35(1):91-99][Ferraro S, Ardoino I, Boracchi P, et al. Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. Clin Chim Acta. 2012;413(9-10):888-893. doi: 10.1016/j.cca.2012.01.034][Giampaolo B, Angelica M, Antonio S. Chromogranin ‘A’ in normal subjects, essential hypertensives and adrenalectomized patients. Clin Endocrinol (Oxf). 2002;57(1): 41-50. doi: 10.1046/j.1365-2265.2002.01557.x][Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: 10.1210/jc.2014-1498][Mahapatra NR, O’Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005;115(7):1942-1952. doi: 10.1172/JCI24354][O’Toole D, Grossman A, Gross D, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009;90(2):194-202. doi: 10.1159/000225948][Friese RS, Altshuler AE, Zhang K, et al. MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. Hum Mol Genet. 2013;22(18):3624-3640. doi: 10.1093/hmg/ddt213][Sahu BS, Mohan J, Sahu G, et al. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. J Cell Sci. 2012;125(Pt 9):2323-2337. doi: 10.1242/jcs.103176][Chen Y, Rao F, Rodriguez-Flores JL, et al. Naturally occurring human genetic variation in the 3’-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol. 2008;52(18):1468-1481. doi: 10.1016/j.jacc.2008.07.047][Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med. 2003;114(1):25-30. doi: 10.1016/S0002-9343(02)01425-0][Januszewicz W, Kabat M, Prejbisz A, Januszewicz A. Pathogenesis of essential hypertension - a half of the century perspective. Pol Merkur Lekarski. 2014;36(211):7-10][Johnson RJ, Feig DI, Nakagawa T, et al. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens. 2008;26(3):381-391. doi: 10.1097/HJH.0b013e3282f29876][Bachetti T, Ferrari Bardile A, Aloi TL, et al. Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. Int J Cardiol. 2017;236:438-443. doi: 10.1016/j.ijcard.2017.02.019][Goetze JP, Hilsted LM, Rehfeld JF, Alehagen U. Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. Endocr Connect. 2014;3(1):47-56. doi: 10.1530/EC-14-0017][Jansson AM, Rosjo H, Omland T, et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J. 2009;30(1):25-32. doi: 10.1093/eurheartj/ehn513][Estensen ME, Hognestad A, Syversen U, et al. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J. 2006;152(5):927 e921-926. doi: 10.1016/j.ahj.2006.05.008][Sahu BS, Sonawane PJ, Mahapatra NR. Chromogranin A: a novel susceptibility gene for essential hypertension. Cell Mol Life Sci. 2010;67(6):861-874. doi: 10.1007/s00018-009-0208-y][Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007;64(22):2863-2886. doi: 10.1007/s00018-007-7254-0][Takiyyuddin MA, Neumann HP, Cervenka JH, et al. Ultradian variations of chromogranin A in humans. Am J Physiol. 1991;261(4 Pt 2):R939-944. doi: 10.1152/ajpregu.1991.261.4.R939]